INTRODUCTION
Amyloidosis is the generic term for a group of disorders that share common dysfunctions in protein misfoldings. Such defects lead to soluble proteins aggregating into insoluble amyloid fibrils [1] [2] [3] [4] [5] , which in turn results in functional and structural organ damage. Individuals with chronically increased SAA [serum AA (amyloid protein A)] levels may develop AA amyloidosis [6] . During systemic amyloidosis, proteolytic removal of C-terminal amino acids [7] [8] [9] from the precursor results in a 5-10 kDa fibril-forming protein [10, 11] designated AA. These proteins are deposited in vital organs, including the liver, spleen and kidneys [12] . Clinically, AA amyloidosis occurs in patients with rheumatoid arthritis and other chronic inflammatory diseases, and can be induced experimentally in many strains of mice in which SAA concentrations are markedly accelerated by injections of silver nitrate, casein or LPS (lipopolysaccharide) [13] .
Several decades ago, it was observed that an extract of mouse amyloid tissue, given intravenously with simultaneous induction of inflammation, dramatically accelerates AA development [14, 15] . The active accelerating agent was labelled AEF (amyloidenhancing factor). Initial reports described active AEF extract being purified [16] from the spleen of azocasein-treated mice. The identified active component was found to be a highmolecular-mass protein by disc electrophoresis, with no definitive proof for AA. Although discrepancies which revolved around the chemical nature of the AEF existed, nevertheless, the Westermark group firmly established that the amyloid fibrils generated from an amyloidogenic polypeptide by a nucleationdependent process are initiated in vitro by seeding the protein solution with preformed fibrils [17] . By extraction with distilled water according to a modification [18] of an established method [19] , they confirmed that AA fibrils consist mostly of AEF. Increasing evidence indicates that soluble oligomers are associated with early pathological alterations and, strikingly, oligomeric assemblies of different disease-associated proteins may share common structural features. In particular, soluble oligomeric forms of the amyloid-β peptide are the toxic species responsible for neurodegeneration associated with Alzheimer's disease. Therefore the amyloid cascade hypothesis suggests that the mature amyloid fibrils or plaques are less toxic than the prefibrillar aggregates [20] . The toxicity of these early aggregates is believed to result from its intrinsic ability to impair fundamental cellular processes that could eventually lead to apoptotic or necrotic cell death. To date, the role of prefibrillar aggregates/oligomers have not been tested in animals for AEF activity. Moreover, clear-cut explanations to account for the fact that extrahepatically processed AA accumulates at the SAA production site have not been reported. Therefore studies aimed at understanding the lethality caused by early prefibrillar amyloidogenic intermediates will indeed help us to resolve the contribution of SA (systemic amyloidosis) to the amyloid cascade hypothesis. In the present study we wanted to elucidate whether prefibrillar amyloidogenic species (AA oligomers) can stimulate in vivo amyloid deposition in mice. Our investigations substantiate the view that extrahepatic SAA processing might lead to local amyloidogenic processing.
EXPERIMENTAL

Materials
BSA, Coomassie Brilliant Blue, Congo Red, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide], pepstatin, PMSF, RPMI-1640 medium and Thioflavin S were purchased from Sigma. Nitrocellulose membrane was obtained from Millipore. A rat monoclonal antibody against SAA (ab17757) was from Abcam, and IL (interleukin)-1β and TNFα (tumour necrosis factor α) antibodies were obtained from R&D systems. The DAKO mouse anti-human AA antibody used was a gift from Dr G. Merlini (IRCCS Policlinico San Matteo, Pavia, Italy). Casein and dialysis membrane were obtained from Himedia Laboratories. Molecular-mass markers, normal goat serum, HRP (horseradish peroxidase)-conjugated secondary antibodies and DAB (diaminobenzidine) substrate were obtained from Bangalore Genei.
Animals
Adult healthy and virgin Swiss strain male albino mice weighing 25-35 g of between 6 and 8 weeks of age were obtained from Tamil Nadu Veterinary and Animal Sciences University, Chennai, India. They were fed with commercial pellet diet (Hindustan Lever, Bangalore, India) and had free access to water. The experiments were conducted following the guidelines of the animal care committee of the Central Leather Research Institute, Chennai, India.
Partial purification of AEF
AEF was partially purified as described previously [16] with some modifications. It was derived from the spleens of mice, which had received daily (Monday-Friday) subcutaneous injections of 0.5 ml of freshly prepared 10 % casein over a period of 13 days. Harvested spleens were homogenized in 30 % (v/v) glycerol, 10 mM Tris/HCl buffer (pH 7.5) (8 ml/g of spleen). The homogenate was mixed on a rotator for 1 h at 4
• C, and then centrifuged at 250 000 g at 4
• C for 1 h. The supernatant was decanted and either kept frozen for later usage or dialysed for further characterization studies of amyloid protein. The supernatant was dialysed overnight against PBS in a dialysis membrane [MWCO (molecular-mass cut-off) = 12 000 Da], freeze-dried and stored. Protein concentrations were measured using the Lowry method [21] with BSA as the standard. Only the freeze-dried AEF sample was used for all of the experiments in the present work.
Electron microscopy and Congo Red binding studies
For TEM (transmission electron microscopy) studies, the AEF (0.3 mg of protein/ml) was either freshly dissolved or incubated in distilled water at 37
• C for 5 days. A 5 μl aliquot of the protein suspension was applied over 200-mesh carbon-coated copper grids. After washing with MilliQ water, the wet sample on the grid was negatively stained with 2 % (w/v) uranyl acetate in water. Specimens were viewed in a Technai 10 Philips transmission electron microscope at 20 kV. For Congo Red binding studies, 10 μl of the sample was coated on bioadhesive hydrophobic printed slides and allowed to dry for 2 h. The dried sample was gently layered with one drop of 1 mM Congo Red in 10 mM phosphate buffer and 100 mM NaCl (pH 7.4). After 1 min, the slide was tilted at a 30
• angle, the dye was carefully aspirated by slow suction and samples were then rinsed with a drop of water. The slide was dried at room temperature (30 • C), viewed on a OLYMPUS BX 50 polarizing microscope under a cross polarizer equipped with a LINKAM THMS 600 heating stage. The images were captured using a Nikon Coolpix 4500 spot digital camera.
MS
LC (liquid chromatography) ESI (electrospray ionization) mass spectra were recorded on a Bruker Daltonics Esquire 3000 Plus ion trap mass spectrometer attached to an Agilent 1100 series HPLC system. The AEF was dissolved in MilliQ deionized water at a protein concentration of 2 mg/ml. Active fractions of AEF sample were partitioned and isolated through a reverse-phase HPLC using a C 18 column (UltraPac, 4.0 mm × 250 mm; LKB), and by application of a gradient elution (5-95 % acetonitrile). A binary solvent delivery system {solvent A [0.1 % TFA (trifluoroacetic acid) in water] and solvent B (0.1 % TFA in acetonitrile)} was utilized at a flow rate of 0.25 ml/min for 55 min duration. The data was acquired over a m/z range of 500-3000 in positive-ion mode and analysed via MS using Esquire analysis software. An average of 5 spectra was taken with an accumulation time of 110 μs. The deconvoluted mass of each spectrum was then taken for molecular-mass prediction. MALDI-TOF (matrix-assisted laserdesorption ionization-time-of-flight) spectra were acquired on an Ultraflex Bruker mass spectrometer, equipped with a nitrogen laser of wavelength 337 nm. Samples were prepared by mixing equal amounts of protein with the matrix solution (α-cyano-4-hydroxycinnamic acid) saturated with 0.1 % TFA and acetonitrile (1:1). The MALDI spectral analysis was recorded from m/z 500 to 120 000.
Western blotting
The protein extracts of fresh AEF were separated discontinuously on SDS/PAGE (6-15 % gradient gels) and electroblotted on to nitrocellulose membrane. Samples containing approx. 75 μg of protein were applied to the gel and electrophoresed at 60 V for 180 min. For Western blotting, protein extracts of AEF were obtained by ultracentrifugation (50 000 rev./min for 1 h at 4
• C; Beckman LE80 model) using the modified homogenizing buffer [30 % (v/v) glycerol, 10 mM Tris/HCl (pH 7.5), 10 mM NaCl, 1 % (v/v) Triton X-100, 0.02 % NaN 3 , 0.1 mM EDTA, 1 μM pepstatin and 0.2 mM PMSF]. The protein non-specific sites were blocked by incubation in 5 % (w/v) non-fat dried skimmed milk and 0.1 % Tween 20. The membranes were incubated with a rat monoclonal antibody to SAA followed by HRP-conjugated secondary antibodies, and bands were visualized using DAB substrate.
CD spectroscopy
The CD spectra were recorded in a quartz cell with an optical path of 0.1 cm using a Jasco J-715 spectropolarimeter. Five cumulative readings at a 1-nm bandwidth, a resolution of 0.2 nm, a sensitivity of 10 mdeg, a response time of 2 s and a scan speed of 50 nm/min were taken, averaged, smoothed, and subsequently the baseline was subtracted. The percentages of the secondary structures were calculated using the SELCON3 program [22] .
FTIR (Fourier-transform IR) studies
FTIR spectra were recorded on a Thermo Nicolet Spectrometer (AVATAR-320 model) at 300 K. Each spectrum was taken with a resolution of 4 cm −1 and an accumulation of 32 scans. Reference spectra were recorded under identical scan conditions with the corresponding solvent in the cell and subtracted from the protein spectra according to previously established criteria [23] . The final spectrum was smoothed and baseline corrected.
AEF activity in vivo
Amyloidosis induction in mice was by the modification of a previously described protocol [17] . The freshly dissolved AEF (containing globular amyloid oligomers) was used for amyloidosis induction rather than protofibrils or fibrils. Mice were divided into two experimental groups, with six animals in each group. In one group each mouse received a single injection of 0.1 ml of AEF (20 μg of protein) diluted in distilled water into the lateral tail vein for 3 days. Another group of mice (control) received 0.1 ml of distilled water alone. Immediately afterwards, both treated and control animals were injected subcutaneously with 0.5 ml of a freshly prepared 2 % solution of silver nitrate in distilled water for 3 days. Additional 0.5 ml doses of silver nitrate were given on the 7th, 9th, 11th and 13th day to both groups. All animals were killed on day 16 by cervical dislocation. The organs such as the liver, kidney and brain were removed, fixed in 10 % buffered formalin and embedded in paraffin for microscopic analyses.
Congo Red and Thioflavin S staining
Sections (10 μm) were deparaffinized, stained with alkaline Congo Red and counterstained with Haematoxylin [24] and examined for the presence of amyloid. The Congo-Red-stained sections were viewed under an OLYMPUS BX 50 polarizing microscope under a cross polarizer equipped with a LINKAM THMS 600 heating stage. The images were captured using a Nikon Coolpix 4500 spot digital camera. For Thioflavin S staining in brain, sections were deparaffinized, rehydrated and incubated in 1 % Thioflavin S for 10 min, then decolorized in 95 % ethanol and distilled water and mounted in glycerin jelly. The sections were examined with an OLYMPUS CK 40 fluorescent microscope.
Immunohistochemistry
Antibody staining on paraffin-embedded tissue sections was performed as described previously [25] . The DAKO mouse antihuman AA antibody was diluted 1:100 in PBS containing 1 % normal goat serum, 1 % BSA and 0.03 % Triton X-100 and incubated with sections overnight at 4
• C. For IL-1β and TNFα immunoreactivity the working dilution of the primary antibody was 15 μg/ml in PBS containing 1 % normal goat serum, 1 % BSA and 0.03 % Triton X-100. Sections were then washed three times for 5 min each in PBS and incubated with an antimouse secondary antibody peroxidase conjugate for 60 min. Immunoreactivity was detected with 0.05 % DAB and 0.03 % H 2 O 2 . After colour development with DAB substrate, the reaction was stopped by washing with distilled water. Before mounting, the slides were counterstained with Meyer's Haematoxylin solution for 2 min.
RESULTS
Globular compared with fibrillar morphologies of AEF
AEF was characterized using Congo Red staining and TEM. Partially purified amyloid-laden protein extracts that dissolved easily into distilled water were defined as fresh AEF. Another set, the 'aged samples', were prepared by incubating the partially purified protein extracts in water for 5 days. After staining with Congo Red, the fresh AEF did not show fibrillar characteristics in polarized light, whereas the aged AEF sample revealed birefringence in polarized light which showed the presence of amyloid fibrils ( Figure 1A ). The TEM picture of fresh AEF showed circular bodies with the diameter ranging from 10 to 65 nm that could account for the structure of small and large globular diffusible amyloid oligomers ( Figure 1B) . In contrast, the TEM image of aged AEF revealed only mature fibrils rather than oligomers or protofibrils. Interestingly, electron micrographs of negatively stained aged AEF ( Figures 1C and 1D ) revealed both branching (8.2 nm width) and non-branching (10 nm width) fibril morphology. In addition intertwining of two or more fibrils ( Figure 1C ) was seen in non-branching fibrillar networks. Thus the above results clearly substantiate the existence of globular oligomers in partially purified AEF from amyloid-laden spleens of mice.
MS is an important tool for characterization of AEF
To gain structural insight of the amyloidogenic material present in partially purified amyloid-laden spleen extract (AEF), MS (MALDI-TOF and LC ESI-MS) characterization was performed. The MALDI spectrum obtained for fresh AEF is shown in the mass range from m/z 6000 to 17 000 in Figure 2 . Interestingly, several minor and major peaks at m/z 6409, 6636, 7227, 7318, 7818, 7909, 8214, 9032, 9304, 9682, 9818, 10015 and 10360 could be obviously seen in the mass range from m/z 6000-10500. The peaks characterized in this region could account for the structure of 5-10 kDa AA aggregates/oligomers with predominating 8.2 kDa AA species rather than proteolytic monomers. This is because the AEF sample was dialysed (MWCO = 12 000 Da) prior to MALDI spectral analysis. Moreover, the most noticeable thing in the MALDI spectral region is the prevalence of a peak at m/z 11636, which depicts the significance of full-length SAA in the active preparation. The importance of some of the non-amyloidogenic peaks (as represented by arrows) with m/z 14605, 14870 and 15548 is not known. In order to shed better light on the unit structure of the 5-10 kDa AA proteins and A-SAA (acute-phase SAA) molecule present in AEF, we carried out LC ESI-MS. In the deconvoluted ESI mass spectra, a total of 54 components were observed (see Supplementary Table S1 at http://www.BiochemJ.org/bj/ 415/bj4150207add.htm). Interestingly, in accordance with the MALDI results, the 5-10 kDa AA proteins present in AEF were not identified as monomers in the deconvoluted ESI which clearly substantiates the absence of proteolytic monomers in the AEF. Instead several components of varying magnitude with the deconvoluted masses ranging from 13 to 80 kDa were eluted during ESI operation and detected in the ESI that might account for the oligomeric size of each of the 5-10 kDa AA proteins ( Figure 3B ). Consistent with this, the unit mass of each of the proteolytic AA (5-10 kDa) subspecies was not predictable in the ESI. Interestingly a component eluted with the deconvoluted Figure S1A and S1B (at http://www.BiochemJ.org/bj/415/bj4150207add.htm).
Anti-SAA immunoblotting uncovers polymeric heterogeneity in AEF preparations
Anti-SAA immunoblotting was performed to elucidate the size of the AA oligomers present in AEF. As shown in Figure 4 , several SAA immunoreactive species could be obviously seen in the mass range from 13 to 80 kDa that could account for the structure of diffusible globular amyloid oligomers. A band with an apparent molecular mass of 12 kDa noticeable on the blot is consistent with SAA monomers. Therefore it is plausible to support the notion that small and medium-sized AA oligomers constitute the partially purified spleen AEF. Although full-length SAA monomers are present in AEF, only globular amyloid oligomers could be functional for AA amyloidosis induction in mice.
Spectroscopic studies reveal more sheet-like assemblies in aged AEF preparations
The secondary structure of AEF was characterized using CD and FTIR spectroscopic studies. As shown in Figure 5 (A) (curve a) and Table 1 , the CD spectrum of fresh AEF showed a mixture of helix (45.1 %), random (23.8 %), turn (17.8 %) and sheet (10.6 %) conformations. In the aged AEF ( Figure 5A , curve b, and Table 1 ), the observed secondary structures were random (39.6 %), helix (26.6 %), sheet (17.3 %) and turn (18.6 %) respectively. From the CD results it is clear that the freshly dissolved AEF (amyloid oligomers) adopts a predominant helixcoil mixture, whereas after an incubation period of 5 days with water, a secondary structural shift towards β-sheet conformation is favoured, thereby assisting fibril formation. The FTIR spectra taken for AEF are shown in Figure 5 (B). In the amide I region, the emphasized bands between 1640 and 1660 cm −1 are generally attributed to α-helix and unordered structures, and bands from 1640 to 1620 cm −1 are assigned to β-sheets. In agreement with this prevailing notion, a greater abundance of α-helix and random coil could be obviously seen in the fresh AEF ( Figure 5B, curve a) . The other minor bands at 1629, 1690 and 1675 cm −1 would be consistent with the antiparallel β-sheet and turn structures. In the aged sample ( Figure 5B , curve b), the amide I vibrational wavenumbers critical for β-sheet (1618 and 1636 cm −1 ) and random (1640 cm −1 ) conformations are noticeably increased, with a considerable decrease in helix (1651 cm −1 ) content. Thus, as was the case with the CD analysis, the FTIR spectral changes indicate the increased sheet-forming propensity of AA aggregates/oligomers as a function of time.
Studies of AEF effects in vivo through histology and immunohistochemical studies
To date there is no clear-cut evidence to account for the fact that diffusible amyloid oligomers have AEF activity. In the present study, we show for the first time that an intravenous injection of protein extract containing globular amyloid oligomers can induce SA in mice. Interestingly, the partially purified AEF material comprising globular oligomers triggered AA amyloidosis in vital organs, as evidenced from the histology and -6I ) of amyloid-oligomer-induced SA mice, whereas no amyloid deposit could be seen in the tissues of control mice. The presence of AA amyloid in the cerebrovasculature of SA mice is shown by both immunohistochemical ( Figure 6I ) and Thioflavin S staining techniques ( Figures 6J and 6K) . In contrast, a Thioflavin S positive signal was not observed in the brain of control mice. In addition, the expression of some key pro-inflammatory cytokines such as IL-1β and TNFα was highly altered in the kidney (Figures 6L and 6M) and brain ( Figures 6N and 6O ) of SA mice brain, thus supporting the notion of a dysfunctional consequence of AEF. In particular, we show that given certain situations of systemic dysfunction, circulating AEF (fresh globular oligomers) can cross the blood-brain barrier, lodge into cerebral tissue, and might trigger the local amyloidogenic cascade to enhance amyloid production. It has been shown recently that a defective bloodbrain barrier might allow the soluble amyloid peptides to target neurons in the brain [26] . 
DISCUSSION
Over the years, technical impediments have hampered efforts to isolate and characterize AEF from extracts of AA-laden mouse tissue and hence we lacked precise information on its chief constituents. In the present study we explored the possibility of using MALDI-TOF, ESI-MS, CD, FTIR, TEM and immunoblotting techniques to gain direct structural insight on partially purified spleen AEF. Taken together the results suggest that the active material in the AEF comprises globular diffusible AA oligomers and SAA monomers. Therefore it is clear that the above investigations serve to gain novel structural insights on the accumulation of prefibrillar amyloidogenic molecules in amyloid-infected tissue. Since it is apparent to notice both the proteolytic aggregate and monomeric precursor in spleen AEF, the fact that extrahepatic SAA processing [6, 27] might lead to local amyloidogenic accumulation at the SAA production site [6] is consistent. These findings compel us to perform further investigations to explore this intriguing phenomenon in other tissues. In fact the present MS approach is the first conclusive evidence to show SAA processing in non-hepatic tissue.
Elucidating the secondary structure of prefibrillar amyloidogenic intermediates/oligomers possesses technical challenges owing, in part, to their limited stabilities [28] in vitro. In the present study we apparently notice a secondary structural shift from α-helical to β-sheet during the conversion of diffusible amyloid oligomers (AEF) into fibrils through CD and FTIR investigations. Moreover the TEM results suggest strongly the existence of globular diffusible amyloid aggregates/oligomers rather than protofibrils or fibrils in fresh AEF. Obviously they could be recognized as small rounded and circular bodies of various widths that could be consistent with previous reports on β oligomers [29] and lysozyme aggregates [30] suggesting the early stages of the nucleation phase of oligomeric intermediates. Since it is interesting to notice the branching and non-branching fibril networks in the aged AEF ( Figures 1C and 1D ), this could be one of the astonishing and notable features in AA amyloid fibril kinetics which was not reported previously. Perhaps some of them grow independently to result in non-branching networks. It is widely considered that fibril unwinding and branching may be essential for the post-nucleation growth process [31, 32] .
There are also concerns about the proteolytic cleavage sites of the SAA precursor. Convincing results suggest that AA is cleaved mostly along the C-terminal [9, 33] to form 5-10 kDa species [7, 10, 11] . Although it is assumed that cleavage could be a prefibrillogenic event, a considerable body of experimental evidence is still lacking to support this view. Therefore this is believed to be one of the challenging perspectives in the AA-amyloid research. The present MALDI, ESI-MS and anti-SAA immunoblotting results suggest strongly the occurrence of a prefibrillogenic cleavage process, owing to the prevalence of proteolytic aggregates and SAA monomers at the splenic extracellular site.
It is well known that AA fibrils can accelerate amyloid deposition in vital organs of liver, spleen and kidney after 48 h when injected along with silver nitrate and could dramatically shorten the lag phase by 2-3 weeks of inflammatory stimuli. In the present case, a single dose of AEF and silver nitrate showed minute amounts of amyloid in liver and kidney after 48 h. Marked amyloid deposition was noticed only after 5 days (results not shown). We suggest that the AEF effect is due to diffusible aggregates/oligomers of AA. This clearly supports the view that prefibrillar AA oligomers act in a similar manner to its fibrillar counterpart [17] , whereby systemic inflammation in mice bestows a nucleation seeding effect towards the target tissue. However, the finding could also be explained with an autonucleation-dependant mechanism [17] for AA fibrils. A hypothetical model summarizing the functions of diffusible amyloid oligomers in systemic amyloidosis propagation is shown in Figure 7 . Obviously, the seeding effect of such diffusible amyloid oligomers is due to their intricate ability to enter into the systemic circulation, so that the local amyloidogenic cascade is altered in target tissues in association with marked inflammatory responses that in turn triggers amyloid production.
The accumulation of AA fibrils in liver, spleen and kidney [12] is a very common event in experimental murine amyloidosis, but brain deposition remains quite elusive. Here the amyloid deposits in brain could be due to cleavage of brain-specific SAA owing to constitutive overexpression of the SAA gene in the mouse brain [34] during chronic inflammatory conditions. Hence expression of the murine SAA gene should have different unprecedented control in mouse brain, suggesting that the protein itself may have a different physiological role there. However, during the acutephase reaction, extrahepatic tissue-specific patterns of expression of SAA genes in kidney, spleen, thymus, heart, brain, lung, testis and epididymis have also been reported [35] . Increased SAF (SAA-activating factor) activity was also observed in the liver, lung and brain tissues under both acute and chronic inflammatory conditions [36] . In a transgenic mouse model, which expresses the amyloidogenic mouse SAA protein in the brain, induction of a systemic acute-phase response in mice followed by elevated cytokine levels enhanced amyloid deposition in the brain, suggesting that systemic inflammation may be a contributing factor to the development of cerebral amyloid [37] . Thioflavin-S-reactive vascular amyloid deposits have also been reported in the brain following an LPS-mediated acute-phase response, which is in good agreement with the present results [37] . Moreover the same group has also insisted that systemic injection of LPS could alter the expression of IL-1β, IL-6 and TNFα in the brain, which correlates the direct involvement of inflammation with the initiation of the amyloid cascade in the brain. This speculation opens the intriguing possibility that cytokine induction by diffusible prefibrillar AA oligomers and inflammation might also initiate a cascade of intracellular changes that control the post-transcriptional fate of brain SAA mRNA. Hence cytokines can modulate systemic functions by direct actions on the brain. 
Figure S1 LC ESI-MS (liquid chromatography electrospray ionization MS) of AEF (amyloid-enhancing factor) showing the distribution of non-amyloidogenic peaks
The observed charge states and m/z values in ESI-MS shows the deconvoluted masses [14675 and 14837 Da (A) and 15616 Da (B)] of non-amyloidogenic peaks in AEF. 
